Gradient RP-HPLC method for the determination of potential impurities in atazanavir sulfate

Journal of Pharmaceutical and Biomedical Analysis

Volumn 55, Issue 1, 2011, Pages 31-47

  Chitturi, Sreenivasa Rao ^a   Somannavar, Yallappa Somappa ^a   Peruri, Badarinadh Gupta ^a   Nallapati, Sreenivas ^a   Sharma, Hemant Kumar ^a   Budidet, Shankar Reddy ^a   Handa, Vijay Kumar ^a   Vurimindi, Hima Bindu ^b  

^a Department of Analytical research   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Atazanavir sulfate; Isolation and characterization; Method development and validation; Order of reaction; Potential impurities

Indexed keywords

ATAZANAVIR; POTASSIUM DIHYDROGEN PHOSPHATE;

ACCURACY; ACIDITY; ALKALINITY; ARTICLE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG IMPURITY; DRUG OXIDATION; ELUTION; FLOW RATE; HUMIDITY; INFRARED SPECTROSCOPY; LIQUID CHROMATOGRAPHY; PH; PHARMACOLOGIC STRESS TESTING; PHOTOLYSIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY CONTROL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; THERMOSTABILITY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; HIV PROTEASE INHIBITORS; HYDROGEN-ION CONCENTRATION; KINETICS; LIMIT OF DETECTION; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PYRIDINES; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TANDEM MASS SPECTROMETRY; TECHNOLOGY, PHARMACEUTICAL;

EID: 79951768985     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.01.002     Document Type: Article

References (30)

1. Physician's Desk Reference 2009, Thomson Reuters, NJ, USA, 3299-3310. 63rd edition.
2. ter Heine R., Davids M., Rosing H., van Gorp E.C.M., Mulder J.W., van der Heide Y.T., Beijnen J.H., Huitema A.D.R. Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B 2009, 877:575-580.
3. ter Heine R., Rosing H., van Gorp E.C.M., Mulder J.W., van der Steeg W.A., Beijnen J.H., Huitema A.D.R. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J. Chromatogr. B 2008, 867:205-212.
4. D'Avolio A., Siccardi M., Sciandra M., Lorena B., Bonora S., Trentini L., Di Perri G. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J. Chromatogr. B 2007, 859:234-240.
5. ter Heine R., Alderden Los C.G., Rosing H., Hillebrand M.J.X., van Gorp E.C.M., Huitema A.D.R., Beijnen J.H. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2007, 21:2505-2514.
6. Dickinson L., Robinson L., Tjia J., Khoo S., Back D. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2005, 829:82-90.
7. Koal T., Burhenne H., Roemling R., Svoboda M., Resch K., Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19:2995-3001.
8. Colombo S., Beguin A., Telenti A., Biollaz J., Buclin T., Rochat B., Decosterd L.A. Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B 2005, 819:259-276.
9. Crommentuyn K.M.L., Rosing H., Hillebrand M.J.X., Huitema A.D.R., Beijnen J.H. Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J. Chromatogr. B 2004, 504:359-367.
10. Jemal M., Rao S., Gatz M., Whigan D. Liquid chromatography-tandem mass spectrometric quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human peripheral blood mononuclear cells (PBMC): practical approaches to PBMC preparation and PBMC assay design for high-throughput analysis. J. Chromatogr. B 2003, 795:273-289.
11. Schuster A., Burzawa S., Jemal M., Loizillon E., Couerbe P., Whigan D. Quantitative determination of the HIV protease inhibitor atazanavir (BMS-232632) in human plasma by liquid chromatography-tandem mass spectrometry following automated solid-phase extraction. J. Chromatogr. B 2003, 788:377-386.
12. Cattaneo D., Maggiolo F., Ripamonti D., Perico N. Determination of atazanavir in human plasma by high-performance liquid chromatography with UV detection. J. Chromatogr. Sci. 2008, 46:485-489.
13. Seshachalam U., Narasimha Rao D.V.L., Haribabu B., Chandrasekhar K.B. Determination of atazanavir in the presence of its degradation products by a stability-indicating LC method. Chromatographia 2007, 65:355-358.
14. Keil K., Hochreitter J., DiFrancesco R., Zingman B.S., Reichman R.C., Fischl M.A., Gripshover B., Morse G.D. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Ther. Drug Monit. 2007, 29:103-109.
15. Verbesselt R., van Wijngaerden E., de Hoon J. Simultaneous determination of 8 HIV protease inhibitors in human plasma by isocratic high-performance liquid chromatography with combined use of UV and fluorescence detection: amprenavir, indinavir, atazanavir, ritonavir, lopinavir, saquinavir, nelfinavir and M8-nelfinavir metabolite. J. Chromatogr. B 2007, 845:51-60.
16. Loregian A., Pagni S., Ballarin E., Sinigalia E., Parisi S.G., Palu G. Simple determination of the HIV protease inhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection. J. Pharm. Biomed. Anal. 2006, 42:500-505.
17. Rezk N.L., Crutchley R.D., Yeh R.F., Kashuba A.D.M. Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther. Drug Monit. 2006, 28:517-525.
18. Sparidans R.W., Dost F., Crommentuyn K.M.L., Huitema A.D.R., Schellens J.H.M., Beijnen J.H. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. Biomed. Chromatogr. 2006, 20:72-76.
19. Cateau E., Tornier N., Dupuis A., le Moal G., Venisse N. Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography. J. Pharm. Biomed. Anal. 2005, 39:791-795.
20. Tribut O., Verdier M.C., Arvieux C., Allain H., Michelet C., Bentue-Ferrer D. Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma. Ther. Drug Monit. 2005, 27:265-269.
21. Poirier J.M., Robidou P., Jaillon P. Simple and simultaneous determination of the HIV-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir, plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. Ther. Drug Monit. 2005, 27:186-192.
22. Dailly E., Raffi F., Jolliet P. Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz). J. Chromatogr. B 2004, 813:353-358.
23. Colombo S., Guignard N., Marzolini C., Telenti A., Biollaz J., Decosterd L.A. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. J. Chromatogr. B 2004, 810:25-34.
24. ICH Guideline, Stability Testing of New Drug Substances and Drug Products, Q1A (R2), 6 February, 2003.
25. ICH Guideline, Impurities in New Drug Substances, Q3A (R2), October 25, 2006.
26. ICH Guideline, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, Q7, November 2000.
27. ICH Guideline, Q2 (R1), Validation of Analytical Procedures, Text and Methodology, November 2005.
28. Xu Z., Singh J., Schwinden M.D., Zheng B., Kissick T.P., Patel B., Humora M.J., Quiroz F., Dong L., Hsieh D.M., Heikes J.E., Pudipeddi M., Lindrud M.D., Srivastava S.K., Kronenthal D.R., Mueller R.H. Process research and development for an efficient synthesis of the HIV protease inhibitor BMS-232632. Org. Process Res. Dev. 2002, 6:323-328.
29. Snyder L.R., Kirkland J.J., Glajch J.L. Practical HPLC Method Development March 1997, John Wiley & Sons Inc., New York. 2nd edition.
30. European Pharmacopeia, 6.4, 2009, Council of Europe, Strasbourg, France, pp. 4407-4413.